AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25372004 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation of the primary motor cortex (tDCS, 1 mA for 20 minutes)
Number of subjects: 20
Study 25372004 — intervention group
Group type: COMPARATOR
Intervention: Placebo transcranial stimulation
Number of subjects: 20
Study 22858697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (10 mmol/L)
Number of subjects: 10
Study 22858697 — intervention group
Group type: COMPARATOR
Intervention: Control (no ferrous sulfate)
Number of subjects: 10
Study 19910548 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drink/wk
Number of subjects: 21860
Study 19910548 — intervention group
Group type: COMPARATOR
Intervention: <1 drink/wk
Number of subjects: 21860
Study 18182830 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tryptophan depletion (RTD)
Number of subjects: 22
Study 18182830 — intervention group
Group type: COMPARATOR
Intervention: Tryptophan-balanced amino acid mixture (BAL)
Number of subjects: 22
Study 15064585 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hEPO administration
Number of subjects: 0
Study 15064585 — intervention group
Group type: COMPARATOR
Intervention: Control group (no r-hEPO administration)
Number of subjects: 0
Study 11394604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular morphine (5 mg)
Number of subjects: 62
Study 11394604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 9721822 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (N = 20)
Number of subjects: 38
Study 9721822 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (N = 10)
Number of subjects: 38
Study 9721822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 8)
Number of subjects: 38
Study 7993153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (200 micrograms once daily)
Number of subjects: 232
Study 7993153 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine tablets (60 mg twice daily)
Number of subjects: 232
Study 7993153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study 7993153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate
Number of subjects: 232
Study 7993153 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine tablets
Number of subjects: 232
Study 7993153 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 232
Study 2786959 — intervention group
Group type: COMPARATOR
Intervention: Toothbrushing only
Number of subjects: 119
Study 2786959 — intervention group
Group type: EXPERIMENTAL
Intervention: Three types of dental floss
Number of subjects: 119
Study 31973633 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring system
Number of subjects: 30
Study 31973633 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 30755054 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 241
Study 30755054 — intervention group
Group type: EXPERIMENTAL
Intervention: RV‐to‐pulmonary artery shunt
Number of subjects: 241
Study 30755054 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 241
Study 30755054 — intervention group
Group type: EXPERIMENTAL
Intervention: RV ejection fraction <40% at 14 months
Number of subjects: 241
Study 27135960 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Tranexamic Acid (20 mg/kg)
Number of subjects: 123
Study 27135960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (3 g/100 mL saline)
Number of subjects: 123
Study 27135960 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 123
Study 25453395 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized diet alone
Number of subjects: 62
Study 25453395 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized diet with VSL#3 (2 capsules per day)
Number of subjects: 62
Study 25453395 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3 in subgroup with low-grade inflammation
Number of subjects: 62
Study 25453395 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 62
Study 23218100 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 332
Study 23218100 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 332
Study 23218100 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 332
Study 23218100 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 332
Study 23218100 — intervention group
Group type: EXPERIMENTAL
Intervention: All atypical antipsychotics
Number of subjects: 332
Study 21949049 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SFA (HS) diet for 4 weeks
Number of subjects: 367
Study 21949049 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference (HS), high-MUFA (HM), or low-fat (LF) diet for 24 weeks
Number of subjects: 367
Study 21949049 — intervention group
Group type: EXPERIMENTAL
Intervention: P:S ratio ≤ 0.33
Number of subjects: 367
Study 21949049 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing P:S ratio (≤0.33 to >0.65; 0.34 to >0.65)
Number of subjects: 367
Study 21949049 — intervention group
Group type: EXPERIMENTAL
Intervention: P:S × genotype interaction
Number of subjects: 367
Study 21949049 — intervention group
Group type: EXPERIMENTAL
Intervention: PPARG Ala12 allele carriers
Number of subjects: 367
Study 18688547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg/day iron supplement
Number of subjects: 114
Study 18688547 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg/day iron supplement
Number of subjects: 114
Study 18688547 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/week iron supplement
Number of subjects: 114
Study 18688547 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 114
Study 16941319 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 4% detergent (CHG)
Number of subjects: 20
Study 16941319 — intervention group
Group type: EXPERIMENTAL
Intervention: Propan‐2‐OL (70% by volume; Iso 70)
Number of subjects: 20
Study 16941319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 85% (E 85)
Number of subjects: 20
Study 16941319 — intervention group
Group type: COMPARATOR
Intervention: Propan‐1‐OL (N 60) - reference disinfection procedure
Number of subjects: 20
Study 15246630 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1 virus-like particle vaccine
Number of subjects: 0
Study 15246630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11704601 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled steroids alone or associated with oral steroids
Number of subjects: 0
Study 11704601 — intervention group
Group type: COMPARATOR
Intervention: Steroid-untreated asthmatics
Number of subjects: 0
Study 9449059 — intervention group
Group type: EXPERIMENTAL
Intervention: 235 to 250 lux treatment
Number of subjects: 0
Study 9449059 — intervention group
Group type: COMPARATOR
Intervention: less than 1 lux treatment
Number of subjects: 0
Study 8493453 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg by mouth 4 times a day)
Number of subjects: 306
Study 8493453 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO (500 mg by mouth 4 times a day)
Number of subjects: 306
Study 8493453 — intervention group
Group type: COMPARATOR
Intervention: Control group (electrocoagulation of liver secondaries alone)
Number of subjects: 306
Study 3307367 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 107
Study 3307367 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 107
Study 31676585 — intervention group
Group type: EXPERIMENTAL
Intervention: Magic therapy intervention group (n = 47)
Number of subjects: 190
Study 31676585 — intervention group
Group type: EXPERIMENTAL
Intervention: Magic therapy intervention group (n = 34)
Number of subjects: 190
Study 31676585 — intervention group
Group type: EXPERIMENTAL
Intervention: Health professionals (n = 37 total: 9 physicians, 8 nurses, 20 pediatric residents)
Number of subjects: 190
Study 27287251 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedural anticoagulation (unfractionated or low-molecular-weight heparins or fondaparinux)
Number of subjects: 5239
Study 27287251 — intervention group
Group type: COMPARATOR
Intervention: No post-procedural anticoagulation
Number of subjects: 5239
Study 26063319 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep needling on bilateral ST25 (group A)
Number of subjects: 96
Study 26063319 — intervention group
Group type: COMPARATOR
Intervention: Shallow needling on bilateral ST25 (group B)
Number of subjects: 96
Study 23529145 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation plus strength training (Train)
Number of subjects: 51
Study 23529145 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (Control)
Number of subjects: 51
Study 21794899 — intervention group
Group type: EXPERIMENTAL
Intervention: Desirudin 15 mg SC twice daily
Number of subjects: 120
Study 21794899 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 units SC thrice daily
Number of subjects: 120
Study 19317886 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV XR 1,000 mg/day
Number of subjects: 158
Study 19317886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 16836555 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 155
Study 16836555 — intervention group
Group type: COMPARATOR
Intervention: Standard transfusion
Number of subjects: 155
Study 12952114 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental control (EC)
Number of subjects: 40
Study 12952114 — intervention group
Group type: COMPARATOR
Intervention: Unchanged environment (UE)
Number of subjects: 40
Study 10711866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.04 mg/kg twice a day for 2 days
Number of subjects: 9
Study 10711866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1.0 mg/kg twice a day for 2 days
Number of subjects: 9
Study 10711866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9377855 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA) AUC 5.5-11 (400-800 mg/m2), Cyclophosphamide (CTX) 1500-2500 mg/m2, Etoposide (VP-16) 450-550 mg/m2, G-CSF 5 mg/kg/day from day 4 to day 17, Thymopentin (TP5) 1 mg/kg on alternate days from day 4 to day 30
Number of subjects: 12
Study 7794289 — intervention group
Group type: EXPERIMENTAL
Intervention: Autohaler Inhalation Device (breath-activated MDI)
Number of subjects: 20
Study 7794289 — intervention group
Group type: COMPARATOR
Intervention: Standard MDI
Number of subjects: 20
Study 7794289 — intervention group
Group type: EXPERIMENTAL
Intervention: Autohaler
Number of subjects: 20
Study 3898835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate administered every six hours
Number of subjects: 155
Study 3898835 — intervention group
Group type: COMPARATOR
Intervention: Antacid given hourly
Number of subjects: 155
Study 29926012 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 0
Study 29926012 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study 27229709 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 0
Study 27229709 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 0
Study 24814479 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg)
Number of subjects: 26
Study 24814479 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust with N-acetylcysteine
Number of subjects: 26
Study 24814479 — intervention group
Group type: COMPARATOR
Intervention: Diesel exhaust with placebo
Number of subjects: 26
Study 22697448 — intervention group
Group type: EXPERIMENTAL
Intervention: Guiando a Niños Activos (GANA)
Number of subjects: 58
Study 22697448 — intervention group
Group type: COMPARATOR
Intervention: standard PCIT
Number of subjects: 58
Study 22697448 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 58
Study 20721516 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 15
Study 20721516 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 15
Study 20721516 — intervention group
Group type: COMPARATOR
Intervention: CO25%
Number of subjects: 15
Study 20721516 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 15
Study 20721516 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia exercise
Number of subjects: 15
Study 18831606 — intervention group
Group type: EXPERIMENTAL
Intervention: Brake dynamics manipulated such that deceleration was proportional to pedal position
Number of subjects: 2
Study 18831606 — intervention group
Group type: COMPARATOR
Intervention: Brake dynamics manipulated such that deceleration was proportional to both pedal position and current speed
Number of subjects: 2
Study 15972451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg/d orally) for 14 days
Number of subjects: 2
Study 15972451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg/day) for hypercholesterolemics
Number of subjects: 2
Study 15972451 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 2
Study 12194391 — intervention group
Group type: EXPERIMENTAL
Intervention: MEMBRANE IN SYRINGE technique
Number of subjects: 20
Study 12485551 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed antibiotic prescriptions
Number of subjects: 26
Study 10036599 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel 75 micrograms/day
Number of subjects: 989
Study 10036599 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel 30 micrograms/day
Number of subjects: 989
Study 7984540 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg/d
Number of subjects: 176
Study 7984540 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/d
Number of subjects: 176
Study 7984540 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Diltiazem 300 mg and Enalapril 20 mg
Number of subjects: 176
Study 3140687 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (M)
Number of subjects: 40
Study 3140687 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (T)
Number of subjects: 40
Study 30999110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1489
Study 30999110 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 1489
Study 28601101 — intervention group
Group type: EXPERIMENTAL
Intervention: Not‐on‐Tobacco (N‐O‐T)
Number of subjects: 232
Study 28601101 — intervention group
Group type: EXPERIMENTAL
Intervention: Not‐on‐Tobacco with a physical activity module (N‐O‐T+FIT)
Number of subjects: 232
Study 28601101 — intervention group
Group type: COMPARATOR
Intervention: Brief Intervention (BI)
Number of subjects: 232
Study 25432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 16 weeks
Number of subjects: 163
Study 25432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/extended-release (ER) niacin 2 g/day
Number of subjects: 163
Study 25432415 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg
Number of subjects: 163
Study 25432415 — intervention group
Group type: EXPERIMENTAL
Intervention: ER niacin 2 g/day added to atorvastatin 10 mg
Number of subjects: 163
Study 22684982 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-based behavioral counseling (6 sessions over 3 months)
Number of subjects: 135
Study 22684982 — intervention group
Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 135
Study 22684982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 135
Study 21911844 — intervention group
Group type: EXPERIMENTAL
Intervention: Progress-framed story
Number of subjects: 175
Study 21911844 — intervention group
Group type: COMPARATOR
Intervention: Disparity-framed story
Number of subjects: 175
Study 18057052 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 20
Study 18057052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17017486 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 0
Study 17017486 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective estrogen receptor modulators (SERMs)
Number of subjects: 0
Study 12971707 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (1 hour, three times weekly)
Number of subjects: 40
Study 12971707 — intervention group
Group type: COMPARATOR
Intervention: Control group (medical treatment only)
Number of subjects: 40
Study 10949773 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8939232 — intervention group
Group type: EXPERIMENTAL
Intervention: 15.0 g iodine diluted 1:1
Number of subjects: 138
Study 8939232 — intervention group
Group type: COMPARATOR
Intervention: 15.0 g iodine undiluted
Number of subjects: 138
Study 8939232 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5 g iodine diluted 1:1
Number of subjects: 138
Study 8939232 — intervention group
Group type: COMPARATOR
Intervention: 15.0 g iodine diluted 3:1
Number of subjects: 138
Study 8939232 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine concentration (varied)
Number of subjects: 138
Study 1348161 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol and alprazolam
Number of subjects: 28
Study 1348161 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol with placebo
Number of subjects: 28
Study 30353590 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g/kg S‐DDGS
Number of subjects: 200
Study 30353590 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 g/kg S‐DDGS
Number of subjects: 200
Study 30353590 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 g/kg S‐DDGS
Number of subjects: 200
Study 30353590 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 g/kg S‐DDGS
Number of subjects: 200
Study 30353590 — intervention group
Group type: COMPARATOR
Intervention: 0 g/kg S‐DDGS (control)
Number of subjects: 200
Study 30353590 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing S‐DDGS
Number of subjects: 200
Study 29471147 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light PDT (400 nm)
Number of subjects: 3
Study 29471147 — intervention group
Group type: COMPARATOR
Intervention: Red light PDT (635 nm)
Number of subjects: 3
Study 26792796 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Stories™ intervention (goal-setting session followed by a manualised toolkit for creating Social Stories)
Number of subjects: 50
Study 26792796 — intervention group
Group type: COMPARATOR
Intervention: Attention control (goal-setting session followed by attention control)
Number of subjects: 50
Study 24708660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (Ferinject®)
Number of subjects: 450
Study 24708660 — intervention group
Group type: COMPARATOR
Intervention: Normal (0.9%) saline (placebo)
Number of subjects: 450
Study 22967500 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (7-hour duration)
Number of subjects: 18
Study 22967500 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (7-hour duration)
Number of subjects: 18
Study 20419963 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous closure technique using 5/0 proline double ended suture
Number of subjects: 60
Study 20419963 — intervention group
Group type: COMPARATOR
Intervention: Interrupted closure technique using 5/0 prolene double ended sutures
Number of subjects: 60
Study 19223671 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments
Number of subjects: 14
Study 19223671 — intervention group
Group type: COMPARATOR
Intervention: Control (no garments)
Number of subjects: 14
Study 15937294 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered via three infusions at Weeks 0, 2, and 6
Number of subjects: 22
Study 15937294 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusions
Number of subjects: 22
Study 12371908 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10367949 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with recombinant hepatitis B vaccine
Number of subjects: 41
Study 10367949 — intervention group
Group type: COMPARATOR
Intervention: Reference group receiving standard three-dose vaccination (0, 1, and 6 months)
Number of subjects: 41
Study 7675948 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 5 mg
Number of subjects: 145
Study 7675948 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg
Number of subjects: 145
Study 7675948 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam 0.5 mg
Number of subjects: 145
Study 7675948 — intervention group
Group type: EXPERIMENTAL
Intervention: nitrazepam 5 mg
Number of subjects: 145
Study 7675948 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 145
Study 2041051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 21
Study 2041051 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention diet
Number of subjects: 21
Study 7272161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg four times daily)
Number of subjects: 19
Study 7272161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30429050 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased withdrawal of heart failure medications
Number of subjects: 51
Study 30429050 — intervention group
Group type: COMPARATOR
Intervention: Continuation of heart failure medications
Number of subjects: 51
Study 30429050 — intervention group
Group type: COMPARATOR
Intervention: Continuation of heart failure medications (after initial 6 months)
Number of subjects: 51
Study 27723271 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib monotherapy (4 mg once daily)
Number of subjects: 588
Study 27723271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of baricitinib and MTX
Number of subjects: 588
Study 27723271 — intervention group
Group type: COMPARATOR
Intervention: MTX monotherapy (once weekly)
Number of subjects: 588
Study 27723271 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib plus MTX
Number of subjects: 588